GEN Exclusives

More »

GEN News Highlights

More »
Oct 19, 2007

GSK Licenses BioWa Tool for Antibody R&D

  • GlaxoSmithKline (GSK) gained access to BioWa's Potelligent® technology for the development of antibody-dependent cellular cytotoxicity (ADCC) enhanced antibodies.

    The agreement grants GSK nonexclusive rights to research and develop antibodies based on this platform for an undisclosed number of targets. In return, BioWa will receive an upfront payment and license fees.

    Potelligent improves potency and efficacy of antibody therapeutics by enhancing ADCC, according to BioWa. It reduces the amount of fucose in the carbohydrate structure of an antibody using a fucosyltransferase-knockout CHO cell line as a production cell.


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »